February 9, 2023 11:09 AM ESTUpdated 12:11 PM
R&D
Pharma

Up­dat­ed: Ab­b­Vie leaves some on­col­o­gy pro­grams out of 2023 pipeline high­lights

Kyle LaHucik

Senior Reporter

In an in­vestor up­date Thurs­day morn­ing, Ab­b­Vie left eight pro­grams out of its pipeline high­lights it shared with in­vestors, as com­pared to what ex­ists on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times